End-Stage Renal Disease (ESRD)Symptoms, Doctors, Treatments, Advances & More
Learn About End-Stage Renal Disease (ESRD)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Emory University Hospital Midtown Campus
Janice Lea is a Nephrologist practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 38 years. Dr. Lea is rated as an Elite provider by MediFind in the treatment of End-Stage Renal Disease (ESRD). She is also highly rated in 4 other conditions, according to our data. Her clinical expertise encompasses Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Renovascular Hypertension, Nephrosclerosis, and Kidney Transplant. Dr. Lea is board certified in American Board Of Internal Medicine, 1994.
East Tennessee Medical Associates, P.C.
Lara Kfoury is a Nephrologist practicing medicine in Johnson City, Tennessee. Dr. Kfoury is rated as a Distinguished provider by MediFind in the treatment of End-Stage Renal Disease (ESRD). She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Acute Kidney Failure, End-Stage Renal Disease (ESRD), Chronic Kidney Disease, and Nephrosclerosis. Dr. Kfoury is board certified in American Board Of Internal Medicine.
Bassett Medical Center
Eric Knight is a Nephrologist practicing medicine in Cooperstown, New York. Dr. Knight is rated as a Distinguished provider by MediFind in the treatment of End-Stage Renal Disease (ESRD). He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses End-Stage Renal Disease (ESRD), Chronic Kidney Disease, Pseudohypoaldosteronism Type 2, and Liddle Syndrome.
Summary: The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).
Summary: The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2)....